Evidence map›Paper›PMID 42453421›Full record

ArticleActa pharmaceutica Sinica. B2026

High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay.

Yue Wei, Yunyun Gao, Ruijie Li, Yao Chen, Wenjing Bai, Peirui Zhao, Junchi Hu, Linfeng Li, Xing Wang, Guobing Yin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yue WeiBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Breast and Thyroid Surgery of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Yunyun GaoBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Breast and Thyroid Surgery of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Ruijie LiBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Breast and Thyroid Surgery of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Yao ChenBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Breast and Thyroid Surgery of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Wenjing BaiInstitute of Drug Discovery, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Peirui ZhaoBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Breast and Thyroid Surgery of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Junchi HuBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Breast and Thyroid Surgery of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Linfeng LiBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Breast and Thyroid Surgery of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Xing WangDepartment of Breast and Thyroid Surgery of the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Guobing YinDepartment of Breast and Thyroid Surgery of the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Yongjun DangBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Breast and Thyroid Surgery of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
Xiangqian KongInstitute of Drug Discovery, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Zufeng GuoBasic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Breast and Thyroid Surgery of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Target-based drug screening typically relies on biochemical or affinity-based assays to identify compounds that modulate or bind to purified target proteins

Indexed as

Cellular ligand discoveryDestabilizing mutationsKRASProtein stability-based screeningTarget-based drug screening

Identifiers

PMID42453421
PMCPMC13366234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.